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Besides nuclear retinoid receptors and cellular retinoid binding proteins also retinoic acid (RA)-synthesizing enzymes (using
all-trans-retinal as substrate) and RA-catabolizing enzymes (producing hydroxylated products) may explain the specific
effects of retinoids. In the past we have established an active role for 4-hydroxy-RA and 4-oxo-RA, which originally were
considered to be inactive retinoids, but in fact are highly active modulators of positional specification in Xenopus
evelopment. Here we present evidence for a specific role of hydroxylated RA metabolites in the onset of neuronal
ifferentiation. 4-Hydroxy- and 18-hydroxy-RA are products of the hydroxylation of RA by a novel cytochrome P450
CYP)-type of enzyme, CYP26, expression of which is rapidly induced by RA. P19 embryonal carcinoma (EC) cell lines stably
xpressing hCYP26 undergo extensive and rapid neuronal differentiation in monolayer at already low concentrations of RA,
hile normally P19 cells under these conditions differentiate only in endoderm-like cells. Our results indicate that the
ffects on growth inhibition and RARb transactivation of P19 EC cells are mediated directly by RA, while the onset of
neuronal differentiation and the subsequent expression of neuronal markers is mediated by hCYP26 via the conversion of
RA to its hydroxylated products. © 1999 Academic PressKey Words: embryonal carcinoma; P450; CYP26; neuronal; retinoid.
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(INTRODUCTION
Vitamin A and its analogues, the retinoids (including the
active metabolite retinoic acid (RA)),2 have been shown to
e important regulators of cellular growth, differentiation,
nd morphogenesis (De Luca et al., 1994; Gudas et al.,
994). Moreover these molecules are believed to act as
rucial signal molecules during vertebrate embryonic devel-
pment (Gudas, 1994), like the development of the limb,
he central nervous system (CNS), the heart, the vertebrae,
1 To whom correspondence should be addressed. Fax: 31-30-
2516464. E-mail: paul@niob.knaw.nl.
2 Abbreviations used: CYP, cytochrome P450; HPLC, high-
erformance liquid chromatography; RA, all-trans-retinoic acid;
-oxo-RA, 4-oxo-all-trans-retinoic acid; 4-hydroxy-RA, 4-hydroxy-
ll-trans-retinoic acid; 18-hydroxy-RA, 18-hydroxy-all-trans-
etinoic acid; 9-cis-RA, 9-cis-retinoic acid; 13-cis-RA, 13-cis-
etinoic acid; RAR, retinoic acid receptor; RARE, retinoic acid
esponsive element; RT, reverse transcriptase; RXR, retinoid X
eceptor; TLC, thin layer chromatography; FCS, fetal calf serum.
390nd neural crest derivatives. This is supported by the fact
hat retinoid deficiency during pregnancy often results in
ongenital abnormalities of the embryo, while exposure to
etinoids at elevated levels is teratogenic. The effects of RA
re mediated at different levels, but most importantly
hrough gene transcription, via interactions with multiple
uclear receptors (RARs and RXRs) which are members of
he steroid/thyroid/vitamin D superfamily of nuclear recep-
ors and use RA and 9-cis-RA as high-affinity ligands
Mangelsdorf et al., 1994). RAR–RXR heterodimers bind to
RA response elements (RAREs) in the promoter regions of
target genes and regulate transcription in a ligand-
dependent manner (Zhang et al., 1995; Chambon, 1996).
Additionally, multiple enzymatic pathways to synthesize
as well as metabolize RA exist and may contribute to the
profound effects of retinoids (Napoli et al., 1995).
4-Hydroxy-RA and 4-oxo-RA, two metabolites of RA, are
formed by a CYP-mediated reaction involving RA-
hydroxylase (CYP26) (Ray et al., 1997; White et al., 1997;
Sonneveld et al., 1998; Sonneveld and van der Saag, 1998).
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391Induction of Neuronal Differentiation by CYP26Until recently, 4-hydroxylation of RA was considered to be
an inactivation pathway during growth and differentiation
(Williams et al., 1987). However, in contrast, 4-oxo-RA was
found to be a highly active metabolite which can modulate
positional specification in early amphibian embryos
(Pijnappel et al., 1993) and is a potent inducer of in vivo
roliferation of growth-arrested A spermatogonia in VAD
ouse testis (Gaemers et al., 1996). CYP26 has originally
een cloned from wound epithelium of zebrafish regenerat-
ng caudal fin (White et al., 1996), and mouse (Ray et al.,
997; Abu-Abed et al., 1998), human (White et al., 1997),
nd Xenopus (Hollemann et al., 1998) homologues have
lso been cloned. CYP26 expression is inducible by RA,
nvolving RARs, and has been studied in a variety of human
nd mouse cell lines and tissues (Ray et al., 1997; White et
l., 1997; Abu-Abed et al., 1998; Marikar et al., 1998;
onneveld et al., 1998; de Roos et al., 1999).
We wanted to study a possible role for CYP26 in the
ifferentiation of P19 embryonal carcinoma (EC) cells.
YP26 expression is induced by RA within 2 h in P19 EC
ells, and coincides with RA metabolism in isolated P19
icrosomes. Stable expression of human CYP26 in P19 EC
ells resulted in increased RA metabolism to more polar
ompounds as, e.g., 4-hydroxy-RA and 18-hydroxy-RA, de-
reased growth inhibition by RA and decreased transactiva-
ion of a RARb promoter reporter construct by RA, suggest-
ng an RA inactivation role for CYP26 as proposed earlier
White et al., 1997; Ray et al., 1997). Strikingly, ectopic
expression of CYP26 in P19 cells resulted in neuronal
differentiation—in monolayer—in the presence of low lev-
els RA, normally leading to endodermal differentiation, and
this neuronal differentiation could be inhibited by the CYP
inhibitor liarozole. Finally, the neuronal P19-hCYP26
transfectants evolved into electrically active neurons as
measured as excitable cells by patch-clamp analysis. In
summary, our results indicate that CYP26 expression is
involved in neuronal differentiation of P19 EC cells, possi-
bly via the generation of specific active RA metabolites.
The observations suggest an active role for CYP26 in early
neuronal development.
MATERIALS AND METHODS
Materials. DF medium (1:1 mixture of Dulbecco’s minimal
essential medium and Ham’s F12, buffered with 44 mM NaHCO3)
nd fetal calf serum (FCS) were obtained from Life Technologies
Gaithersburg, MD). Liarozole fumarate (R-75251) was a gift from
r. W. Wouters (Janssen Research Foundation, Beerse, Belgium)
nd was dissolved at a concentration of 10 mM in ethanol and
tored at 280°C. [11, 12-3H]RA (52 Ci/mmol) was obtained from
upont–New England Nuclear (Boston, MA). RA, 13-cis-RA (both
igma Chemicals Co., St. Louis, MO), 4-oxo-RA, 4-hydroxy-RA,
nd 18-hydroxy-RA (all gifts from L. H. Foley, Roche Pharmaceu-
icals, Nutley, NY) and 9-cis-RA (gift from Dr. J. Bausch,
offmann–La Roche, Basel) were dissolved in DMSO at a concen-ration of 10 mM. Am80 (gift from Dr. K. Shudo, Tokyo, Japan) was
issolved in ethanol at a concentration of 10 mM. Retinoids were
t
(
Copyright © 1999 by Academic Press. All righttored in the dark at 280°C. All handling of retinoids was done in
nitrogen atmosphere in a room illuminated with red light only.
urther dilutions of all used retinoids were prepared in culture
edium.
Cell culture and DNA transfection. P19 cells (clone
19S1801A1; McBurney and Rogers, 1982) were cultured as mono-
ayers on 0.1% (v/v) gelatin-coated tissue culture dishes (Costar
orp., Cambridge, MA) in DF medium containing 7.5% fetal calf
erum. To induce differentiation in monolayer, cells were plated at
density of 10.000 cells/cm2 and incubated with 1 mM RA for 4
ays. Transfections were performed by the calcium phosphate
recipitation procedure. To obtain stable hCYP26 transformants,
19 cells were transfected at 40–70% confluence in 50-mm dishes
ith 7.5 mg of pSG5-neo-hCYP26 (Sonneveld et al., 1998). Trans-
formants were selected with 200 mg/ml G418 (Life Technologies,
Gaithersburg, MD). After 2 weeks, G418-resistant colonies were
isolated, cultured under prolonged G418 selection, and analyzed by
Northern analysis for hCYP26 expression.
Transient transfections. P19 and P19-hCYP26 transfectant
cells were seeded in 24-well tissue culture plates (30.000 cells/
well). After 24 h, cells were transfected with 2 mg reporter plasmid
-14701156hRARb2-luc (Folkers and Van der Saag, 1995) and 0.4 mg
SV2-lacZ plasmid. After 16 h medium was refreshed and cells
ere incubated with different concentrations RA or Am80 (1–100
M) for 24 h. Before harvesting, cells were rinsed twice with PBS
nd lysed in 250 ml Triton–lysis buffer (1% (v/v) Triton X-100, 25
mM glycylglycin (pH 7.8), 15 mM MgSO4, 4 mM EGTA, and 1 mM
ithiothreitol) for 30 min at 4°C. Cell extracts were analyzed for
uciferase activity using the Luclite luciferase gene reporter assay
it (Packard, Canberra, CT) and chemiluminescence was measured
n a Topcount scintillation counter (Packard). Values were normal-
zed for transfection efficiency using the b-galactosidase assay
Rosenthal, 1987).
RNA isolation and Northern blot analysis. Total RNA from
ell cultures was extracted by the acid guanidinium thiocyanate
xtraction method (Chomczynski and Sacchi, 1987). Twenty mi-
rograms of total RNA was fractionated on a 0.8% (w/v) agarose gel
ontaining 2.2 M formaldehyde and blotted onto a Hybond C-extra
embrane (Amersham International Ltd., Little Chalfont, Buck-
nghamshire, UK). The 1.6-kb EcoRI-XhoI fragment from human
YP26 cDNA (White et al., 1997), a 1.27-kb PCR fragment of
mouse CYP26 (see Reverse transcription PCR) (Ray et al., 1997),
nd the 1.4-kb PstI fragment from a rat cDNA clone of
lyceraldehyde-3-phosphate dehydrogenase were labeled with
32P]dCTP (Amersham) by random priming to a specific activity of
more than 108 cpm/mg DNA. Hybridization was performed in 50%
v/v) formamide/53 standard saline citrate (SSC)/13 Denhardt’s
solution/0.5% (w/v) sodium dodecyl sulfate (SDS)/10% (w/v) dex-
tran sulfate, and 0.1 mg/ml herring sperm DNA at 42°C for 16 h.
The blots were subsequently washed in 23 SSC/0.1% SDS, 13
SSC/0.1% SDS, 0.13 SSC/0.1% SDS for 20 min at room tempera-
ture and 0.13 SSC/0.1% SDS for 10 min at 65°C. Autoradiography
was for 1–7 days at 280°C using Kodak X-Omat AR film with an
intensifying screen. Signals were quantified by using a Phosphoim-
ager and Image Quant software (Molecular Dynamics, Sunnyvale,
CA).
Reverse transcription PCR. P19 cells were treated with 1 mM
RA for various times and total RNA was isolated. One microgram
of total RNA was incubated with 100 ng oligo(dT)12–18 at 68°C for 5
in and after cooling down to room temperature reverse-
ranscribed using 200 units of Superscript Reverse Transcriptase
Life Technologies, Inc.)/13 Superscript buffer/10 mM dithiotrei-
s of reproduction in any form reserved.
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392 Sonneveld et al.tol, and 500 mM of each dNTP at 37°C for 60 min followed by 5 min
t 68°C. One-fifth of the first-strand product was added to a PCR
mplification mixture, containing 13 Goldstar reaction buffer/1.5
mM MgCl2/200 mM each of the four dNTPs/0.5 Units of Goldstar
Taq polymerase (Eurogentec, Seraing, Belgium)/100 ng of sense
primer 59-CTCAAGCTCTGGGACCTGTA-39, and 100 ng of anti-
sense primer 59-AGGAGGTCCATTTAGAAGCTGCCA-39 corre-
sponding to basepair positions 91–110 and 1359–1336 of mouse
CYP26 (Ray et al., 1997), respectively. Mixtures were overlaid with
mineral oil and amplification was carried out for 39 cycles in a
Perkin–Elmer DNA thermal cycler. Each cycle consisted of 1 min
denaturation at 96°C, 1 min annealing at 56°C, and 2 min exten-
sion at 72°C. The 1267-bp PCR product was purified using a
QIAquick spin-column (Qiagen) and cloned into the pCRII-TOPO
vector (InVitrogen, Carlsbad, CA). Semiquantitative RT-PCR was
performed as described earlier (Itoh et al., 1997; Boudjelal et al.,
1997), using primers for Nscl2, Ngn1, Stra13, Mash1, Activin, and
36B4. Each primer set was tested to be in the linear range of product
formation. PCR reaction products were separated on 0.8% agarose
gels containing Vistra Green (Amersham International Ltd., Little
Chalfont, Buckinghamshire, England) and quantified by using a
FluorImager and Image Quant software (Molecular Dynamics,
Sunnyvale, CA).
Growth inhibition assays. The retinoids’ effects on cell prolif-
eration were examined in [3H]thymidine incorporation assays and
n soft agar growth assays as described earlier (Todaro et al., 1981;
onneveld et al., 1998).
Immunofluorescence. Cells were grown on gelatinized (0.1%
v/v)) coverslips and fixed with 2% (w/v) paraformaldehyde in PBS.
ubsequently, the cells were washed three times with PBS, perme-
bilized with 0.1% Triton X-100/PBS, washed three times with
BS, incubated with 0.5% (w/v) BSA/PBS, and washed two times
ith PBS. Cells were incubated with monoclonal neurofilament
65-kDa (NF-M) antibody (1:1000) in combination with Hoechst
1:500) or monoclonal SSEA-1 antibody (gift from Dr. D. Solter)
1:100) in 10% (v/v) normal goat serum/PBS for 1 h, washed three
imes with PBS, incubated with a TRITC-conjugated second anti-
ody (1:250) in 10% (v/v) normal goat serum/PBS for 1 h, washed
hree times with PBS, and mounted in Moviol. The detection of
mmunostaining was performed by photographing the cells with a
eiss fluorescence microscope using the TRITC filter set.
TLC and HPLC analysis of retinoid metabolites. Near conflu-
nt P19 cultures, grown in 150-mm dishes were treated with 1 mM
A for the indicated times. In the case of P19-hCYP26 transfec-
ants no RA was added, but 7.5% (v/v) FCS was present. Microso-
al fractions were isolated and assayed for enzymatic conversion
f [3H]RA to polar metabolites as described earlier (Sonneveld et al.,
1998) and extracted retinoids were dissolved in 45 ml methanol for
LC analysis or in 125 ml methanol:60 mM ammonium acetate
(9:1, v/v), pH 5.75 for analysis by HPLC. For analysis by HPLC,
retinoids were extracted and fractionated from near confluent cell
cultures as previously described (Van der Leede et al., 1997).
Retinoid extracts were injected into a reverse-phase HPLC system
containing a Spherisorb S50DS2 column (25 3 0.46 cm; Phase
Separations, Inc., Franklin, MA) and separated using gradient
elution with solvent A (60 mM ammonium acetate, pH 5.75) and
solvent B (methanol). The gradient program with a flow rate of 1
ml/min was 5 min isocratic at 65% B, followed by a convex
gradient (number 4; Waters Associates) to 85% B in 15 min, a linear
gradient to 99% B in 10 min, and 10 min isocratic at 99% B.
Radiolabeled retinoids were detected on-line with a LB506 radio-
chromatography monitor (Berthold, Bad Wildbad, Germany)
(
w
Copyright © 1999 by Academic Press. All rightequipped with a Z-1000 flow cell and a scintillant flow rate of 2
ml/min. Radioinert retinoids were run as standards and detected by
measuring the absorbance at 350 nm in a UV flow spectrometer
(Phase Separations). Single retinoid peaks were quantified by inte-
gration of the peak areas using chromatography software program
Winflow version 1.2.1 (Borwin, Le Fontanil, France).
Electrophysiology. P19 cells were aggregated for 4 days in the
presence of 1 mM RA and subsequently replated on gelatinized
coverslips for 3 days. P19-hCYP26 cells (clone P19-hCYP26-10)
were differentiated in the presence of 1 mM RA for several days as
ndicated. Experiments were performed at 33°C, using the whole-
ell configuration of the patch clamp technique (Peppelenbosch et
l., 1995). Responses were recorded through the Axopatch 200B
mplifier (Axon Instruments, Inc., Foster City, CA). Output signals
ere digitized at 2 kHz using a Pentium II personal computer
quipped with a PC1200 AD/DAC data acquisition board (National
nstruments, Austin, TX). The composition of the bath medium
as 140 mM NaCl, 5 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM
glucose, 10 mM Hepes, adjusted to pH 7.45 with NaOH. The
pipette composition was 145 mM KCl, 5 mM NaCl, 1 mM CaCl2,
10 mM EGTA, 2 mM MgCl2, 10 mM Hepes, adjusted to pH 7.30
ith KOH.
RESULTS
CYP26 is rapidly induced in P19 EC cells by RA and
coincides with RA metabolism. P19 EC cells are a useful
in vitro tool to study early processes in embryonal develop-
ment, since this pluripotent stem cells of teratocarcinomas
can differentiate toward endoderm, mesoderm, or ectoderm
in the presence of RA. In various cell types, including
HL-60, MCF-7, and T-47D cells, RA metabolism can be
induced by RA pretreatment (Takatsuka et al., 1996; Van
der Leede et al., 1997; White et al., 1997; Sonneveld et al.,
1998). We and others recently showed that RA metabolism
is the result of the induction of a novel RA-inducible CYP
enzyme, CYP26, which possesses strong RA 4-hydrox-
ylating activity (White et al., 1996; 1997; Marikar et al.,
1998; Sonneveld et al., 1998). Here we addressed the ques-
tion of whether in P19 EC cells CYP26 also can be induced
by RA, resulting in the metabolism of RA. We cloned a
1267-bp fragment of mouse CYP26 by means of RT-PCR
from P19 EC cells and used this fragment in Northern
analysis of RNA isolated from P19 and RAC65 EC cells
pretreated with 1 mM RA for different periods of time.
CYP26 was induced transiently in P19 cells by RA treat-
ment with strong expression between 2 and 24 h of RA
treatment, and expression strongly decreased between 24
and 48 h (Fig. 1). In RA-resistant P19 EC-derived RAC65
cells, expressing a dominant negative RARa, resulting in
decreased RAR function (Kruyt et al., 1992), CYP26 was not
induced by RA (Fig. 1), suggesting that activated RARs are
involved in CYP26 expression. This was already shown for
RARg in F9 EC cells (Abu-Abed et al., 1998) and for all three
ARs (a, b, and g) in human HCT 116 colon carcinoma
cells (Sonneveld et al., 1998) and human keratinocytes
Marikar et al., 1998). Autoinduction of RA metabolism
as studied by TLC analysis (Fig. 2). Isolated microsomes
s of reproduction in any form reserved.
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393Induction of Neuronal Differentiation by CYP26(200 mg protein) of untreated and RA-treated P19 and
AC65 EC cells were incubated with [3H]RA for 45 min.
Microsomes of untreated P19 cells incubated with [3H]RA
howed no metabolism of RA, while microsomes of P19
ells pretreated for 2 h with RA already showed metabolic
FIG. 1. Expression of CYP26 in RA-sensitive P19 EC cells versus
reated with 1 mM RA for time periods indicated, total RNA was is
sing mouse CYP26 and GAPDH cDNA as probes.
FIG. 2. Autoinduction of RA metabolism in RA-sensitive P19 EC
cells were treated with 1 mM RA for the periods of time indicated, m
ncubated with 10 nM [3H]RA for 45 min at 37°C. Microsomal reaction
Copyright © 1999 by Academic Press. All rightctivity. This activity was present up to 48 h after RA
retreatment, and RA metabolism closely correlated with
he CYP26 induction profile (Fig. 1). However, RAC65 cells
id not show such fast RA autometabolism (Fig. 2). Only
fter 48 h treatment of RAC65 cells with RA, isolated
resistant RAC65 EC cells. P19 EC cells and RAC65 EC cells were
d, and 20 mg of total RNA was subjected to Northern blot analysis,
versus RA-resistant RAC65 EC cells. P19 EC cells and RAC65 ECRA-cells
icrosomes were isolated, and 200 mg of microsomal protein was
products were extracted and separated by TLC.
s of reproduction in any form reserved.
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394 Sonneveld et al.microsomes were capable of converting [3H]RA into more
polar metabolites. In summary, in RA-sensitive P19 EC
cells CYP26 can be induced by RA, resulting in RA metab-
olism, while in RA-resistant RAC65 EC cells this is not the
case, probably due to impaired RAR function.
P19 EC cell lines stably expressing human CYP26 show
increased RA metabolism. To study the function of the
CYP26 gene in RA-mediated differentiation of P19 cells, we
produced P19 cells, stably transfected with human CYP26
cDNA under control of the SV40 early promoter.
Neomycin-resistant clones were screened for CYP26 ex-
pression by Northern blot analysis using human CYP26
cDNA as a probe, and three clones expressing the transgene
(with high, moderate, and low expression levels) were
selected: P19-hCYP26-10, P19-hCYP26-14, and P19-
hCYP26-55 (Fig. 3A). These clones were tested for enzy-
matic activity of the introduced CYP26 by incubating
isolated microsomes with the CYP26 substrate [3H]RA for
45 min and analysis of the retinoid products by HPLC
(Sonneveld et al., 1998). Parental P19 microsomes isolated
from untreated P19 EC cells could not metabolize [3H]RA,
hile microsomes of all three selected clones (P19-
CYP26-10, P19-hCYP26-14, and P19-hCYP26-55) were
learly capable of converting RA to more polar metabolites
ncluding 4-hydroxy-RA (peak 2) as the major compound,
ut also 18-hydroxy-RA (peak 3), 4-oxo-RA (peak 1), and
wo unidentified peaks (Figs. 3C–3F). Besides the microso-
al assay, we also tested P19 cells and P19-hCYP26 cells
or their ability to metabolize RA. P19 and P19-hCYP26
ells were incubated with 10 nM [3H]RA for various times
and the RA content in the cells was measured by HPLC
analysis (Fig. 4). P19 cells were capable of metabolizing RA.
Within 6 h, 50% of the RA had been converted, although no
polar metabolites like 4-hydroxy-RA and 4-oxo-RA could be
detected (data not shown). P19 cells pretreated with 1 mM
A for 16 h, containing induced CYP26 activity (Fig. 1), and
table P19-hCYP26 transfectants showed clear increased
A metabolism compared to the parental P19 EC cells.
ithin 2 h, 50% of the RA had disappeared, and after 6 h no
A could be detected (Fig. 4). In conclusion, all three
19-hCYP26 clones expressed functional CYP26 enzyme
apable of metabolizing RA into more polar metabolites
ike 4-hydroxy-RA and 18-hydroxy-RA, as determined by
he microsomal assay as well as in intact cells.
P19-hCYP26 stable transfectants are decreased in
rowth inhibition by RA. Treatment of P19 EC cells with
A results in cell growth inhibition as shown by decreased
roliferation and loss of the capacity for anchorage-
ndependent growth (Rayner and Graham, 1982). To study
he result of CYP26 expression in P19 on RA-induced
rowth inhibition, we compared the growth behavior of the
19-hCYP26 transfectants with the P19 parental cells in
he presence and absence of RA by means of [3H]thymidine
ncorporation in monolayer culture and growth assays in
oft agar (Fig. 5). P19 EC cells were very sensitive to RA and
emonstrated a concentration-dependent inhibition: Treat-
ent of P19 cells with 1 nM RA showed only 46% [3H]thy-
Copyright © 1999 by Academic Press. All rightidine incorporation (Fig. 5A) and 25% colony formation
Fig. 5C) compared to untreated P19 cells. Treatment of P19
ells with 100 nM RA completely inhibited growth as
etermined in both assays. However, two P19-hCYP26
ransfectants showed clearly decreased growth inhibition
y RA compared to P19 cells. Treatment with 1 nM RA
ardly influenced the growth of the P19-hCYP26 transfec-
ants in both assays, while 10 nM RA showed around 50%
3H]thymidine incorporation and 50% colony formation
compared to 20 and 10%, respectively, for P19 cells).
owever, one of the P19-hCYP26 clones (P19-hCYP26-55)
howed no decreased growth inhibition by RA in the
3H]thymidine incorporation assay and was comparable
ith P19 cells (Fig. 5A). To determine whether the de-
reased growth inhibition of the P19-hCYP26 transfectants
y RA is indeed caused by CYP26 activity, we also per-
ormed growth inhibition assays with the synthetic retinoid
m80, which at low concentrations is selective for RARa
(Graupner et al., 1991; Roy et al., 1995). Previously we
howed that the CYP26 enzyme is highly specific for RA
nd does not recognize Am80 as a substrate (Sonneveld et
l., 1998), and therefore one would expect no difference in
rowth inhibition by Am80 between P19 and P19-hCYP26
ransfectants. This is the case indeed (Fig. 5); both [3H]thy-
idine incorporation (Fig. 5B) and in soft agar growth assays
Fig. 5D) the P19-hCYP26 transfectants showed more or less
he same growth inhibition pattern by Am80 as for P19
ells, comparable to the growth inhibition profile of P19 EC
ells by RA (Figs. 5A and 5C). This suggests that it is RA
tself and not (one of) its metabolites generated by CYP26
hich causes the anti-proliferative effects in P19 EC cells.
Expression of human CYP26 in P19 EC cells results in
ecreased transactivation of a RARb promoter–luc re-
orter by RA. In P19 EC cells, RA can transactivate the
ARb2 gene in a concentration-dependent manner, as de-
ermined by transient transfections of P19 cells with
ARb2 promoter constructs coupled to reporter genes
Kruyt et al., 1992; Folkers and van der Saag, 1995) as well
s in stable P19 cells harboring the 1.8-kb mRARb2 pro-
moter coupled to lacZ (Sonneveld et al., 1999). To study the
effect of CYP26 expression on transactivation of the RARb
gene by RA in P19 cells, we transiently transfected P19 and
P19-hCYP26 transfectants with a 214701156RARb pro-
moter construct (Folkers and van der Saag, 1995) coupled to
the luciferase gene as a reporter. As shown in Fig. 6, the
reporter construct is induced in P19 cells upon RA treat-
ment in a concentration-dependent fashion, with a 200-fold
induction after 24 h by 100 nM RA. The P19-hCYP26
transfectants showed a decreased transactivation of the
promoter as compared with P19 cells. Treatment with 10
nM RA for 24 h did not result in RARb promoter transac-
tivation, while P19 cells showed a 50-fold induction at this
concentration. Even with 100 nM RA treatment for 24 h,
both P19-hCYP26 transfectants showed only a 60-fold in-
duction compared to 200-fold in P19 EC cells. To show that
this decreased transactivation of the RARb promoter in the
P19-hCYP26 transfectants is due to CYP26 activity, we
s of reproduction in any form reserved.
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395Induction of Neuronal Differentiation by CYP26performed the same transfection assay with Am80 as in-
FIG. 3. Expression and RA-hydroxylating activity of CYP26 enz
YP26 in P19-hCYP26 transfectants. Twenty micrograms of RN
APDH cDNA as probes. (B) Elution position of standard retinoi
-cis-RA; 6, RA; Microsomes of P19 (C), P19-hCYP26-10 (D), P19-h
f microsomal protein was incubated with 10 nM [3H]RA for 45 m
the extracts was analyzed by reverse-phase HPLC.ducer. This retinoid, not recognized by CYP26, showed
strong activation of the RARb promoter in P19 cells, in fact, i
Copyright © 1999 by Academic Press. All righteven stronger than RA (Fig. 6). The P19-hCYP26 transfec-
in P19-hCYP26 cells and microsomes. (A) Expression of human
s subjected to Northern blot analysis, using human CYP26 and
, 4-oxo-RA; 2, 4-hydroxy-RA; 3, 18-hydroxy-RA; 4, 13-cis-RA; 5,
6-14 (E), and P19-hCYP26-55 (F) EC cells were isolated and 200 mg
37°C. Reaction products were extracted and the organic phase ofyme
A wa
ds: 1tants showed RARb induction profiles comparable to those
n the parental P19 cells, suggesting again that it is RA and
s of reproduction in any form reserved.
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396 Sonneveld et al.not (one of) its metabolites generated by CYP26 which
causes the strongest RARb induction in P19 EC cells.
hCYP26 promotes neuronal differentiation of P19 EC
cells. Based upon the experiments presented so far, de-
creased growth inhibition by RA and decreased transactiva-
tion of the RARb promoter in the P19-hCYP26 transfec-
ants, we can conclude that biologically active RA is
nactivated via a negative feedback function of CYP26, as
e and others proposed earlier (White et al., 1997; Marikar
t al., 1998; Sonneveld et al., 1998; Sonneveld and Van der
Saag, 1998). To study the effect of CYP26 expression in
RA-induced P19 EC differentiation, we compared differen-
tiation characteristics of P19 EC cells with P19-hCYP26
cells. P19 EC cells are malignant stem cells of mouse
teratocarcinomas that resemble the pluripotent stem cells
of the inner cell mass of preimplantation embryos, and
therefore are widely used as an in vitro model system to
tudy early differentiation events during mammalian em-
ryonic development (Martin, 1980). Murine P19 EC cells
an be differentiated by RA into derivatives of all three
erm layers, i.e., endoderm, mesoderm, and (neuro-)-
ctoderm, depending on the concentration of RA used and
he culture conditions (Bain et al., 1994). When P19 cells are
ggregated and treated with high concentrations of RA (5 3
027 M), cells differentiate into neural cells sharing several
imilarities with neurons of the rostral CNS based on their
henotypes of neurotransmitters and receptors (McBurney
t al., 1982; Bain et al., 1994), while aggregates treated with
low levels of RA (1028 M) differentiate into endodermal-like
cells (McBurney et al., 1982). In monolayer culture, P19 EC
FIG. 4. Metabolism of RA by P19 EC cells and stable P19-hCYP26
derivatives. P19 (n), P19 cells pretreated with 1 mM RA for 16 h (),
19-hCYP26-10 (E), P19-hCYP26-14 (F), and P19-hCYP26-55 (h)
C cells were treated with 10 nM [3H]RA for the periods of time
indicated and harvested and retinoids were extracted. The organic
phase of the extracts was analyzed by reverse-phase HPLC and the
[3H]RA peak was quantified. Results are presented as means 6 SEM
f three experiments.cells can differentiate only toward endodermal and meso-
dermal derivatives when treated with RA for 4 days (Mum-
Copyright © 1999 by Academic Press. All rightery et al., 1986). To examine the differentiation state of
untreated and RA treated P19 and P19-hCYP26 cells, im-
munofluorescence was performed with an antibody against
murine embryonic antigen SSEA-1, which is a marker for
undifferentiated embryonal stem and carcinoma cells (Bal-
lou et al., 1987). Untreated P19 cells all stained positive
(Fig. 7A), while P19 cells treated with 1 mM RA for 4 days
ave lost SSEA-1 staining, indicating complete differentia-
ion of the P19 EC cells (Fig. 7B). However, the P19-hCYP26
ransfectants only show 40–60% EC component (Figs. 7C
nd 7E), while SSEA-1 staining decreased to 20–40% upon
A treatment (Figs. 7D and 7F). On this basis, RA treatment
pparently did not result in complete differentiation of the
19-hCYP26 clones. When P19-hCYP26-10 and P19-
CYP26-14 transfectants growing in monolayer were
reated with 1 mM RA, neurite extensions appeared already
fter 1 day (data not shown). After 3 days of RA treatment,
hese neurite-like structures were extended dramatically
nd cells resembled morphologically neuronal cells, but
lso endoderm-like cells appeared. To examine this neuro-
FIG. 5. Growth inhibition of P19 EC cells and stable P19-hCYP26
transfectants. Dose–response curves showing the effect of RA (A
and C) and Am80 (B and D) on thymidine incorporation (A and B)
and on colony formation in soft agar growth assays (C and D) of P19
(n), P19-hCYP26-10 (E), P19-hCYP26-14 (F), and P19-hCYP26-55
(h) cells, as described under Materials and Methods. Results are
presented as percentages of control and represent means 6 SEM of
three experiments.
s of reproduction in any form reserved.
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in more detail, immunofluorescence was performed with an
antibody against the 165-kDa NF-M protein, which func-
tions as a marker of neuronal differentiation (McBurney et
l., 1988). Untreated and RA-treated (1 mM RA for 3 days)
ild-type P19 cells did not stain positively with the
eurite-specific anti-NF-M antibody (Figs. 7G and 7H).
owever, in untreated P19-hCYP26-10 and P19-hCYP26-14
ransfectants, staining of neurites was already observed
Figs. 7J and 7M), and was strongly increased after 3 days of
A treatment (Figs. 7K and 7N). To study if the observed
euronal differentiation—in monolayer—was due to
YP26 activity, the CYP inhibitor liarozole fumarate
Wouters et al., 1992) was added during the 3 days of RA
reatment. Liarozole was shown to be a potent inhibitor and
an completely block CYP26 enzyme activity (Sonneveld et
l., 1998). Indeed, neuronal differentiation—in monolayer—
bserved in the P19-hCYP26 transfectants upon RA treat-
ent could be severely inhibited by liarozole (Figs. 7L and
O). These findings suggest that CYP26 activity might lead
o the formation of RA metabolites with specific functions
n directing neuronal differentiation.
Altered expression of neuronal markers in P19-hCYP26
ransfectants. Stable expression of human CYP26 resulted
in neuronal differentiation of P19 EC cells under conditions
normally leading to endodermal and mesodermal differen-
tiation of these cells. Even without RA treatment, a part of
FIG. 6. Transactivation of a RARb promoter–luc reporter in P19
P19-hCYP26-14 cells were transiently transfected with a 2147011
after 24 h of treatment with different concentrations of RA or Am
SEM.the P19-hCYP26 transfectant cells was already differenti-
ated and contained neurite-like structures. To determine
Copyright © 1999 by Academic Press. All rightthe neuronal state (early or late) of the human CYP26-
expressing P19 cells, expression of several markers of neu-
ronal differentiation was analyzed by semiquantitative RT-
PCR. This analysis was performed on RNA isolated from
cells cultured in monolayer, untreated or treated with 1 mM
RA up to 4 days. Nscl-2, a basic helix–loop–helix (bHLH)
gene expressed in the developing nervous system (Lipko-
witz et al., 1992) was transiently expressed in P19 wild-type
cells upon differentiation (Fig. 8). The highest expression is
found after 2 days of RA treatment and is decreased rapidly
afterward. In P19-hCYP26 transfectants, however, Nscl-2 is
already expressed without added RA, and expression is
increased after 1–2 days RA of treatment. Neurogenin-1
(ngn1), a novel atonal-related bHLH protein expressed at
early stages of neuronal differentiation and involved in
neuronal determination in vertebrates (Ma et al., 1996;
Sommer et al., 1996), was not expressed in P19 EC cells and
expression was transiently induced by RA treatment. How-
ever, ngn1 expression could already be detected in un-
treated P19-hCYP26 transfectants, and expression was fur-
ther increased by RA treatment in a transient fashion (Fig.
8) with highest expression after 2 days incubation with RA.
Stra13, a novel RA-inducible bHLH gene expressed during
mouse embryogenesis which was shown to promote neuro-
nal differentiation of P19 EC cells (Boudjelal et al., 1997),
was induced upon RA treatment of P19 cells with its
highest expression at day 4 (Fig. 8). In the P19-hCYP26
ells and stable P19-hCYP26 derivatives. P19, P19-hCYP26-10, and
Rb2 promoter–luc construct and luciferase activity was measured
ach point represents the mean of four independent experiments 6EC c
56RAtransfectants, stra13 expression was comparable to that in
P19 EC cells. Mammalian achaete–scute homologue 1
s of reproduction in any form reserved.
FIG. 7. Expression of SSEA-1 and NF-M in P19 EC cells and P19-hCYP26 transfectants. P19 (A, B, and G–I), P19-hCYP26-10 (C, D, and
J–L), and P19-hCYP26-14 (E, F, and M–O) cells were grown on tissue coverslips in monolayer, fixed with 2% (w/v) paraformaldehyde and
stained for SSEA-1 (A–F) or NF-M (G–O) expression. In the case of SSEA-1 staining, immunofluorescence photographs were taken of
untreated cells (A, C, E) and cells treated with 1 mM RA for 4 days (B, D, F). In the case of NF-M staining, immunofluorescence photographs
were taken of untreated cells (G, J, M), cells treated with 1 mM RA for 3 days (H, K, N), or cells treated with 1 mM RA and 10 mM liarozole
for 3 days (I, L, O). The nuclei were counterstained with Hoechst.
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399Induction of Neuronal Differentiation by CYP26(mash1), which is expressed in subsets of neuronal precur-
sor cells in the developing nervous system and required for
the differentiation of autonomic and olfactory sensory neu-
rons (Johnson et al., 1990; Guillemot and Joyner, 1993;
Sommer et al., 1995), was not expressed in P19 EC cells and
could be induced by RA within 1 day (Fig. 8). In the
P19-hCYP26 transfectants, strong mash1 expression was
present in untreated cells, while RA treatment increased
the expression in a transient fashion with strongest expres-
sion after 1 day, which decreased from day 2 of RA treat-
ment onwards. The neuronal markers used in this study for
monolayer experiments were previously shown to be highly
expressed in P19 aggregates (Boudjelal et al., 1997). Expres-
sion of activin, a mesodermal marker (Smith et al., 1990),
was detectable at low level in P19 EC cells, and expression
increased only after 4 days of RA treatment (Fig. 8). In the
untreated P19-hCYP26 transfectants, activin expression
was low and increased upon RA treatment after 1 day (clone
14) toward 3 days (clone 10), showing higher expression
levels than P19 wild-type cells. This indicates that (part of)
the CYP26-expressing P19 cells might differentiate into
mesodermal direction after RA treatment, although the
neuronal direction is favored, as indicated by the constitu-
tive and inducible expression of neuronal markers.
Electrical properties and action potentials in hCYP26-
FIG. 8. Stable expression of human CYP26 in P19 cells results in
an altered expression of neuronal markers. P19, P19-hCYP26-10,
and P19-hCYP26-14 cells were grown in monolayer in the absence
or the presence of 1 mM RA for 1 to 4 days. Total RNA was isolated
nd reverse transcribed and transcripts for each gene were analyzed
y semiquantitative PCR. The amount of reverse transcribed RNA
n each reaction was normalized with transcripts of the 36B4 gene
hat is unresponsive to RA treatment (Krowczynska et al., 1989).expressing P19 EC cells. To study the electrophysiologi-
cal properties of the neuronal P19-hCYP26 transfectants,
i
w
Copyright © 1999 by Academic Press. All rightwe investigated the capacity of those cells to evolve into
electrically active neurons. P19-hCYP26 cells, cultured in
monolayer, were treated with RA for several days, and cells
with neuronal morphology were selected for whole-cell
patch clamp recording (Peppelenbosch et al., 1995). In
addition, P19 cells aggregated for 4 days in the presence of 1
mM RA and replated for 3 days were used as control for
neuronal differentiation. Selected neuron-like cells showed
upon depolarization fast inward currents followed by more
slow outward currents (Fig. 9). The development of the
percentage of excitable cells during the differentiation with
RA, measured as active currents, is shown in Fig. 9A. After
3 days of RA treatment, morphologically identified neuron-
like cells, which already displayed neurofilament staining
(Fig. 7) and expression of several other neuronal markers
(Fig. 8), hardly showed any electrical excitability (only 1 of
15 tested cells was excitable). However, after 4 days of RA
treatment, 72% of the selected cells were electrical excit-
able, increasing up to 90% after 5 days. Representative
examples of patch clamp traces are shown in Fig. 9B (at 2
days RA treatment) and Fig. 9C (at 5 days RA treatment).
So, although P19-hCYP26 cells appear to be neuronal-like
very early after RA treatment based upon morphology and
expression of neuronal markers, electrically active neurons,
which can participate in electrical neuronal signaling, arise
later, from 3 to 4 days after RA treatment.
DISCUSSION
In this paper we report on the role of the recently
identified retinoic acid hydroxylase (CYP26) in differentia-
tion of P19 embryonal carcinoma cells. This enzyme,
mainly responsible for the 4-hydroxylation of RA, is rapidly
inducible by RA in P19 EC cells (within 6 h), and shows
maximal enzymatic activity toward all-trans-RA within
16 h. This fast induction occurs at the level of transcription
regulated by ligand-bound RARs (Abu-abed et al., 1998;
Marikar et al., 1998; Sonneveld et al., 1998). That RARs are
necessary for CYP26 expression is demonstrated by RAC65
EC cells, with disturbed RAR signaling, showing no induc-
tion of CYP26 upon RA treatment (this study), while stable
introduction of RARs (RARa, RARb, or RARg) in this cell
ine results in restored CYP26 expression (E. Sonneveld and
. T. van der Saag, unpublished results) as shown previously
or HCT 116 cells (Sonneveld et al., 1998). CYP26 expres-
ion is rapidly decreased between 24 and 48 h RA treat-
ent. However, Fujii et al. (1997) described CYP26 expres-
ion in P19 EC cells after 2 days RA treatment with
aximal expression after 4 days which disappeared after 8
ays. This could indicate that CYP26 is induced biphasicly
y RA in P19 EC cells, with a first rapid transient induction
etween 2 and 48 h and a second late transient induction
etween 2 and 8 days after RA induction. Whether this
econd transient induction of CYP26 is a direct effect of RA
tself is doubtful, since RA is metabolized completely
ithin 16 h. Therefore, other CYP26 regulatory factors
s of reproduction in any form reserved.
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Copyright © 1999 by Academic Press. All rightmight exist which probably will be identified after isolation
of the CYP26 promoter sequence.
Stable expression of human CYP26 under a constitutive
promoter (SV40) in P19 EC cells results in highly increased
RA metabolism with 4-hydroxy-RA and 18-hydroxy-RA as
predominant metabolites, indicating that the enzyme is
present and active in these transfectants. In these transfec-
tants, RA is cleared from the cells and the medium within
6 h, which normally occurs within 16 h in P19 EC cells. The
metabolic profile of the P19-hCYP26 transfectants is iden-
tical to the profile recently described for RA-treated T-47D
human breast cancer cells and CYP26-overexpressing HCT
116 colon carcinoma cells (Van der Leede et al., 1997;
Sonneveld et al., 1998).
CYP26 is rapidly induced by RA itself in a variety of cell
lines, including EC cells. Induction of CYP26, and as a
consequence RA metabolism, is only possible in cell lines
known to be sensitive for RA, e.g., with respect to growth
inhibition. CYP26-overexpressing P19 EC cells show mark-
edly decreased growth inhibition by RA compared to paren-
tal P19 EC cells, as demonstrated by thymidine incorpora-
tion and colony growth in soft agar. This suggests that
CYP26 activity is not involved in formation of metabolites
that mediate growth inhibition as proposed earlier by
Takatsuka et al. (1996), but rather leads to the formation of
inactive retinoids. This idea is strengthened by the obser-
vation that overexpression of CYP26 in RA-resistant cell
lines (MDA-MB-231 breast tumor cells and HCT 116 colon
carcinoma cells) does not result in restored growth inhibi-
tion by RA (E. Sonneveld and P. T. van der Saag, unpub-
lished results). This indicates a negative feedback function
for CYP26, probably to protect the cell from an overdosage
of RA, as proposed previously for CYP24-involved vitamin
D3 catabolism (Makin et al., 1989). However, new insight in
he function(s) of the formed metabolite 24,25-
ihydroxyvitamin D has been gathered, and specific active
oles for this metabolite have been proposed (reviewed by
t. Arnaud and Glorieux, 1998).
Stable expression of CYP26 in P19 EC cells results in
euronal differentiation of these cells accompanied by early
xpression of several neuronal markers, under conditions
ormally leading to endodermal and mesodermal differen-
iation only. Low levels of retinoids (between 10 and 100
M retinol and 0.1 and 1 nM RA; data not shown) present in
he medium (provided by the serum present) seem to be
ufficient to induce neuronal differentiation of CYP26-
expressing P19 cells since these transfectants already show
neurites in the absence of added RA, while number and
length of the extensions increased dramatically upon RA
aggregates at 4 days differentiation. The voltage protocol is
depicted at the top of B. Traces were corrected for series resistanceFIG. 9. Whole-cell currents of selected P19 cells, P19 aggregates,
nd P19-hCYP26-10 transfectants with a neuronal morphology.
epresentative whole-cell patch-clamp traces showing slow inac-
ivation outward currents evoked on indicated depolarization steps
rom 260 mV holding potential. No active currents were observed
on hyperpolarizing voltage steps (not shown). (A) Development of
the percentage of measured active currents during the differentia-and capacitive currents. Leakage currents were subtracted pro-
grammatically.
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401Induction of Neuronal Differentiation by CYP26treatment. At this point there seems to be contradictory
data. P19 EC cells growing in monolayer will never differ-
entiate into neuronal-like cells, even though CYP26 expres-
sion is induced very fast after RA treatment (within 2 h) and
enzymatic activity is present within 6 h. One could argue
that if CYP26 is essential for neuronal differentiation, P19
cells would undergo neuronal differentiation in monolayer
after RA treatment and the consequent expression of
CYP26. One possibility is the greater amount of metabo-
lites in the CYP26 transfectants, leading to neuronal differ-
entiation. Second, the RA-induced expression of CYP26
might occur too late, e.g., P19 cells may already be com-
mitted to endodermal differentiation by the action of RA
itself (by the super fast induction of endoderm specific
genes) and not its metabolites. In the CYP26-expressing P19
cells, RA treatment directly results in the formation of
hydroxylated metabolites which on their turn might induce
the onset of early neuronal differentiation, via transcription
of neuronal specific genes (mash1, ngn1, nscl2, etc.), a
situation which normally might only occur in P19 aggre-
gates, via mechanisms not known yet. Alternatively, the
rapid clearance of RA in the P19-hCYP26 transfectants
upon RA treatment may result in repression of genes
required for endodermal differentiation, creating a cellular
environment for the activation of neuronal genes as a
default mechanism (Hemmati-Brivanlou and Melton,
1997). RARb seems not to play a role in the onset of
euronal differentiation because in hCYP26-expressing P19
ells a RARb promoter–luciferase reporter construct is
ardly induced by RA, whereas in parental P19 cells induc-
ion of this construct is extensive upon RA treatment. The
act that we obtained multiple hCYP26-expressing P19 EC
lones which show neuronal morphology after RA treat-
ent rules out the possibility that we are dealing with a
lonal artefact. This is furthermore strengthened by the
bservation that embryonic stem (ES) cells stably trans-
ected with hCYP26 also display a neuronal phenotype (E.
onneveld et al., manuscript in preparation).
bHLH proteins comprise an expanding gene family of
ranscription factors of which several members have been
dentified as important regulators of neurogenesis (for re-
iews see Crews, 1998; Dambly-Chaudie`re and Vervoort,
998; Sasai, 1998). Evidence is accumulating that early-
cting bHLH genes such as ngn1, ngn2, and stra13, control
the determination of different proneural cell lineages (Ma et
al., 1996; Sommer et al., 1996; Boudjelal et al., 1997; Fode et
al., 1998; Ma et al., 1998), preceding the expression of bHLH
genes controlling neuronal differentiation, such as mash1,
nscl2, and neuroD (Lipkowitz et al., 1992; Guillemot and
Joyner, 1993; Lee et al., 1995; Sommer et al., 1995; Itoh et
al., 1997), and both types of neural bHLH genes often act in
cascades (Ma et al., 1998). Untreated hCYP26-expressing
P19 EC cells express “early” determination bHLH genes, as
well as “late” differentiation bHLH genes, while expression
of both types is further increased by RA. This expression of
multiple position-specific neuronal markers suggests the
Copyright © 1999 by Academic Press. All rightpresence of various CNS neuronal cell types in the P19-
hCYP26 transfectants or possibly combined in one cell.
The neuronal nature of the hCYP26 expression P19 EC
cells was furthermore confirmed by measuring the electro-
physiological properties of these neuronal cells. Within the
first 3 days of RA treatment, P19-hCYP26 transfectants
showed no electrical excitability, as measured by patch-
clamp currents, but after 5 days almost all selected cells
were excitable. This development of the percentage of
excitable cells during the differentiation of these transfec-
tants by RA treatment is in agreement with electrophysio-
logical properties observed for neuronal P19 and ES aggre-
gates (Jones-Villeneuve et al., 1982; Okabe et al., 1996) and
P19 and ES cells stably transfected with RPTPa, respec-
tively (Den Hertog et al., 1993; Van Inzen et al., 1996). So,
lthough P19-hCYP26 cells appear to be neuronal-like very
arly after RA treatment based upon morphology and ex-
ression of neuronal markers, functionally active neurons
rise later.
That RA is generally involved in the development of the
NS has been known for some time now, based upon RA
epletion, RA overdosage, and RA receptor knock-out stud-
es (Durston et al., 1989; Kastner et al., 1995; Båvik et al.,
996; Maden et al., 1996; Dickman et al., 1997; White et al.,
998). Recent papers now show a specific role for the
etinoid pathway in specifying positional identity and de-
ermination of cells in the CNS (Gould et al., 1998; Socka-
athan and Jessell, 1998; Solomin et al., 1998; Maden et al.,
998; reviewed by Maden, 1998). However, it is not known
f this specific role is due to the direct action of RA itself or
hether it could be caused by specific metabolites of RA.
ased upon in vitro data presented in this paper we suggest
he latter possibility with CYP26 catalyzing the formation
f these metabolites. Isolation and characterization of these
etabolites proves this hypothesis. In addition, CYP26 is
ighly expressed in the developing CNS, such as hindbrain
ctoderm, cephalic mesenchyme (including migrating neu-
al crest cells), and caudal neural plate (Fujii et al., 1997;
rofimova-Griffin and Juchau, 1998; de Roos et al., 1999;
ulianella et al., 1999).
In summary, this paper describes the first report on the
nvolvement of RA metabolism in neurogenesis as studied
y the P19 EC cell system, a well-established in vitro
ystem for studying neuronal differentiation. Furthermore,
he generation of hCYP26-expressing P19 EC cells provides
new, useful, and simplified tool for studying early neuro-
al differentiation in vitro and measurements of fully
ature neurons, bypassing laborious cell aggregation pro-
edures of these cells.
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